Kontour (Xi'an) Medical Technology Co., Ltd. (SHA:688314)
China
· Delayed Price · Currency is CNY 39.48
+1.28 (3.35%)
Mar 10, 2026, 1:15 PM CST
SHA:688314 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 349.6 | 311.71 | 262.63 | 229.61 | 206.31 | Upgrade
|
| Other Revenue | - | 10.23 | 12.4 | 10.34 | 6.24 | Upgrade
|
| Revenue | 349.6 | 321.95 | 275.03 | 239.95 | 212.55 | Upgrade
|
| Revenue Growth (YoY) | 8.59% | 17.06% | 14.62% | 12.89% | 29.54% | Upgrade
|
| Cost of Revenue | - | 67.93 | 60.38 | 50.19 | 41.99 | Upgrade
|
| Gross Profit | 349.6 | 254.01 | 214.65 | 189.76 | 170.56 | Upgrade
|
| Selling, General & Admin | - | 119.76 | 107.33 | 91.58 | 75.18 | Upgrade
|
| Research & Development | - | 23.9 | 17.64 | 18.3 | 16.8 | Upgrade
|
| Other Operating Expenses | 238.62 | 4.64 | 4.42 | 4.03 | 2.77 | Upgrade
|
| Operating Expenses | 238.62 | 147.96 | 129.38 | 114.11 | 94.71 | Upgrade
|
| Operating Income | 110.98 | 106.05 | 85.26 | 75.64 | 75.85 | Upgrade
|
| Interest Expense | - | -2.17 | -1.89 | -1.23 | -0.74 | Upgrade
|
| Interest & Investment Income | - | 5.22 | 5.2 | 8.14 | 4.85 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.37 | 0.23 | 0.49 | 0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.81 | -1.75 | -0.3 | -0.2 | -0.17 | Upgrade
|
| EBT Excluding Unusual Items | 115.79 | 106.98 | 88.5 | 82.85 | 79.82 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -12.59 | -1.86 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.44 | -0.06 | -0 | 0.02 | Upgrade
|
| Asset Writedown | - | -1.87 | - | -0.04 | -0.35 | Upgrade
|
| Other Unusual Items | - | 13.04 | 5.18 | 5.66 | 15.9 | Upgrade
|
| Pretax Income | 115.79 | 106 | 91.75 | 88.46 | 95.39 | Upgrade
|
| Income Tax Expense | 16.97 | 18.37 | 17.28 | 14.3 | 14.21 | Upgrade
|
| Earnings From Continuing Operations | 98.82 | 87.64 | 74.47 | 74.16 | 81.18 | Upgrade
|
| Minority Interest in Earnings | - | 0.76 | 1.04 | 1.53 | 0.44 | Upgrade
|
| Net Income | 98.82 | 88.4 | 75.51 | 75.69 | 81.63 | Upgrade
|
| Net Income to Common | 98.82 | 88.4 | 75.51 | 75.69 | 81.63 | Upgrade
|
| Net Income Growth | 11.79% | 17.07% | -0.23% | -7.28% | 55.83% | Upgrade
|
| Shares Outstanding (Basic) | 81 | 81 | 81 | 81 | 73 | Upgrade
|
| Shares Outstanding (Diluted) | 81 | 81 | 81 | 81 | 73 | Upgrade
|
| Shares Change (YoY) | -0.13% | -0.12% | -0.23% | 11.81% | 19.10% | Upgrade
|
| EPS (Basic) | 1.22 | 1.09 | 0.93 | 0.93 | 1.12 | Upgrade
|
| EPS (Diluted) | 1.22 | 1.09 | 0.93 | 0.93 | 1.12 | Upgrade
|
| EPS Growth | 11.93% | 17.20% | - | -17.07% | 30.84% | Upgrade
|
| Free Cash Flow | - | 92.86 | 71 | 73.78 | 48.05 | Upgrade
|
| Free Cash Flow Per Share | - | 1.15 | 0.87 | 0.91 | 0.66 | Upgrade
|
| Dividend Per Share | - | 0.360 | 0.320 | 0.371 | 0.443 | Upgrade
|
| Dividend Growth | - | 12.50% | -13.84% | -16.14% | 19.25% | Upgrade
|
| Gross Margin | 100.00% | 78.90% | 78.05% | 79.08% | 80.25% | Upgrade
|
| Operating Margin | 31.75% | 32.94% | 31.00% | 31.52% | 35.69% | Upgrade
|
| Profit Margin | 28.27% | 27.46% | 27.46% | 31.54% | 38.40% | Upgrade
|
| Free Cash Flow Margin | - | 28.84% | 25.82% | 30.75% | 22.61% | Upgrade
|
| EBITDA | 122.21 | 117.29 | 95.62 | 85.56 | 83.02 | Upgrade
|
| EBITDA Margin | 34.96% | 36.43% | 34.77% | 35.66% | 39.06% | Upgrade
|
| D&A For EBITDA | 11.24 | 11.24 | 10.36 | 9.91 | 7.17 | Upgrade
|
| EBIT | 110.98 | 106.05 | 85.26 | 75.64 | 75.85 | Upgrade
|
| EBIT Margin | 31.75% | 32.94% | 31.00% | 31.52% | 35.69% | Upgrade
|
| Effective Tax Rate | 14.66% | 17.33% | 18.83% | 16.17% | 14.90% | Upgrade
|
| Revenue as Reported | - | 321.95 | 275.03 | 239.95 | 212.55 | Upgrade
|
| Advertising Expenses | - | 16.02 | 17.77 | 19.97 | 17.68 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.